A novel bioinformatics strategy to uncover the active ingredients and molecular mechanisms of Bai Shao in the treatment of non-alcoholic fatty liver disease

被引:0
作者
He, Shuaibing [1 ,2 ]
Chen, Hantao [1 ,2 ]
Yi, Yanfeng [3 ]
Hou, Diandong [1 ,2 ]
Fu, Xuyan [1 ,2 ]
Xie, Jinlu [1 ,2 ]
Zhang, Juan [4 ]
Liu, Chongbin [1 ,2 ]
Ru, Xiaochen [1 ,2 ]
Wang, Juan [5 ]
机构
[1] Huzhou Univ, Huzhou Cent Hosp, Sch Med, Key Lab Vector Biol & Pathogen Control Zhejiang Pr, Huzhou, Peoples R China
[2] Huzhou Univ, Key Lab Precise Prevent & Control Major Chron Dis, Huzhou, Peoples R China
[3] Huzhou Coll, Sch Sci & Engn, Dept Life Sci & Hlth, Huzhou, Peoples R China
[4] Xinjiang Inst Chinese Mat Med & Ethnodrug, Urumqi, Peoples R China
[5] Zhejiang Pharmaceut Univ, Sch Tradit Chinese Med, Ningbo, Peoples R China
基金
中国国家自然科学基金;
关键词
bioinformatics; Bai Shao; non-alcoholic fatty liver disease; Traditional Chinese Medicine; hepatoprotection; network pharmacology; active ingredient; molecular mechanism; ANIT-INDUCED CHOLESTASIS; TETRACHLORIDE-INDUCED HEPATOTOXICITY; TRADITIONAL CHINESE MEDICINE; NETWORK PHARMACOLOGY; HERBAL MEDICINES; TOTAL GLUCOSIDES; ACTIVATING NRF2; IN-VIVO; PROTECTS; APOPTOSIS;
D O I
10.3389/fphar.2024.1406188
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: As a new discipline, network pharmacology has been widely used to disclose the material basis and mechanism of Traditional Chinese Medicine in recent years. However, numerous researches indicated that the material basis of TCMs identified based on network pharmacology was the mixtures of beneficial and harmful substances rather than the real material basis. In this work, taking the anti-NAFLD (non-alcoholic fatty liver disease) effect of Bai Shao (BS) as a case, we attempted to propose a novel bioinformatics strategy to uncover the material basis and mechanism of TCMs in a precise manner.Methods: In our previous studies, we have done a lot work to explore TCM-induced hepatoprotection. Here, by integrating our previous studies, we developed a novel computational pharmacology method to identify hepatoprotective ingredients from TCMs. Then the developed method was used to discover the material basis and mechanism of Bai Shao against Non-alcoholic fatty liver disease by combining with the techniques of molecular network, microarray data analysis, molecular docking, and molecular dynamics simulation. Finally, literature verification method was utilized to validate the findings.Results: A total of 12 ingredients were found to be associated with the anti-NAFLD effect of BS, including monoterpene glucosides, flavonoids, triterpenes, and phenolic acids. Further analysis found that IL1-beta, IL6, and JUN would be the key targets. Interestingly, molecular docking and molecular dynamics simulation analysis showed that there indeed existed strong and stable binding affinity between the active ingredients and the key targets. In addition, a total of 23 NAFLD-related KEGG pathways were enriched. The major biological processes involved by these pathways including inflammation, apoptosis, lipid metabolism, and glucose metabolism. Of note, there was a great deal of evidence available in the literature to support the findings mentioned above, indicating that our method was reliable.Discussion: In summary, the contributions of this work can be summarized as two aspects as follows. Firstly, we systematically elucidated the material basis and mechanism of BS against NAFLD from multiple perspectives. These findings further enhanced the theoretical foundation of BS on NAFLD. Secondly, a novel computational pharmacology research strategy was proposed, which would assist network pharmacology to uncover the scientific connotation TCMs in a more precise manner.
引用
收藏
页数:25
相关论文
共 50 条
  • [21] Protective effect of traditional Chinese medicine on non-alcoholic fatty liver disease and liver cancer by targeting ferroptosis
    Wu, Qiongbo
    Chen, Zihao
    Ding, Yi
    Tang, Yunting
    Cheng, Yawei
    FRONTIERS IN NUTRITION, 2022, 9
  • [22] Identification of the Non-Alcoholic Fatty Liver Disease Molecular Subtypes Associated With Clinical and Immunological Features via Bioinformatics Methods
    Liu, Ziyu
    Li, Yufei
    Yu, Caihong
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [23] Identification of key genes in non-alcoholic fatty liver disease progression based on bioinformatics analysis
    Li, Lin
    Liu, Huabao
    Hu, Xiaoyu
    Huang, Yi
    Wang, Yanan
    He, Yansha
    Lei, Qingsong
    MOLECULAR MEDICINE REPORTS, 2018, 17 (06) : 7708 - 7720
  • [24] Network pharmacology reveals the multiple mechanisms of Xiaochaihu decoction in the treatment of non-alcoholic fatty liver disease
    Hu, Qichao
    Wei, Shizhang
    Wen, Jianxia
    Zhang, Wenwen
    Jiang, Yinxiao
    Qu, Caiyan
    Xiang, Junbao
    Zhao, Yanling
    Peng, Xi
    Ma, Xiao
    BIODATA MINING, 2020, 13 (01)
  • [25] Network pharmacology reveals the multiple mechanisms of Xiaochaihu decoction in the treatment of non-alcoholic fatty liver disease
    Qichao Hu
    Shizhang Wei
    Jianxia Wen
    Wenwen Zhang
    Yinxiao Jiang
    Caiyan Qu
    Junbao Xiang
    Yanling Zhao
    Xi Peng
    Xiao Ma
    BioData Mining, 13
  • [26] Recent News on Statins for the Treatment of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis
    Athyros, Vasilios G.
    Katsiki, Niki
    Doumas, Michael
    CURRENT VASCULAR PHARMACOLOGY, 2018, 16 (02) : 104 - 106
  • [27] The Inflammasome in Liver Injury and Non-Alcoholic Fatty Liver Disease
    Mehal, Wajahat Zafar
    DIGESTIVE DISEASES, 2014, 32 (05) : 507 - 515
  • [28] Is there any progress in the treatment of non-alcoholic fatty liver disease?
    Emmanuel A Tsochatzis
    George V Papatheodoridis
    World Journal of Gastrointestinal Pharmacology and Therapeutics, 2011, (01) : 1 - 5
  • [29] The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease
    Del Ben, Maria
    Polimeni, Licia
    Baratta, Francesco
    Pastori, Daniele
    Angelico, Francesco
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 83 (01) : 88 - 95
  • [30] Retinoids as Promising Treatment for Non-alcoholic Fatty Liver Disease
    Tsuchiya, Hiroyuki
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2012, 132 (08): : 903 - 909